Drug Profile
Nicotinamide - Biorunx
Latest Information Update: 21 Oct 2021
Price :
$50
*
At a glance
- Originator Chungbuk National University
- Developer Biorunx; Chungbuk National University
- Class Amides; Antiacnes; Antibacterials; Nicotinic acids; Small molecules; Vitamins
- Mechanism of Action Cytokine modulators; DNA-binding protein stimulants; Leukocyte modulators; Transcription factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Non-small cell lung cancer
Most Recent Events
- 18 Oct 2021 No development reported - Phase-II/III for Non-small cell lung cancer (Combination therapy, Late-stage disease) in South Korea (PO)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Cancer in South Korea (PO, Capsule)